Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03397173 · ClinicalTrials.gov registry record · Phase 2
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03397173 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 12 participants.
The verdict
NCT03397173, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of treatment with azacitidine (an FDA approved drug for the treatment of MDS) and high dose ascorbic acid in patients with TET2 mutations. This approach is intended to enhance the enzymatic activity of TET2 protein, which in term may help to improve counts and symptoms, related to Myelodysplastic Syndromes and Acute Myeloid Leukemia. This combination is specific to individuals who carry this mutation.
Interventions
- DRUG Azacitidine
- DRUG Ascorbic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-03-16 |
| Est. Completion | 2021-01-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03397173
The ClinicalTrials.gov registry entry for NCT03397173 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT03397173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03397173 about?
NCT03397173 is a clinical study titled "TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid". The purpose of this study is to evaluate the efficacy of treatment with azacitidine (an FDA approved drug for the treatment of MDS) and high dose ascorbic acid in patients with TET2 mutations. This approach is intended to enhance the enzymatic activity of TET2 protein, which in term may help to impr...
What is the current status of trial NCT03397173?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2018-03-16. Estimated completion is 2021-01-21.
What interventions are being tested in trial NCT03397173?
The interventions under investigation include: Azacitidine (DRUG), Ascorbic acid (DRUG).
Who is sponsoring clinical trial NCT03397173?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.